BCWM
SPRY icon

Ball & Co Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Ball & Co Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,000
Closed -$87K – 91
2025
Q2 		$87K Sell
5,000
-5,000
-50% -$72.1K 0.09% 28
2025
Q1 		$125K Hold
10,000
– – 0.13% 21
2024
Q4 		$105K Buy
+10,000
New +$140K 0.08% 24

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ball & Co Wealth Management's SPRY Position: Q3 2025 in Review

Ball & Co Wealth Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 5,000 shares — an estimated $87K sold.

Ball & Co Wealth Management first reported a position in SPRY in Q4 2024 and held it in 3 quarters. The position peaked at $125K in Q1 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Ball & Co Wealth Management reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ball & Co Wealth Management sold 5,000 ARS Pharmaceuticals shares in Q3 2025, an estimated $87K.
  • Ball & Co Wealth Management first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Ball & Co Wealth Management's ARS Pharmaceuticals position peaked at $125K in Q1 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Ball & Co Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.